Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer

PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodson, Andrew, Okonji, David, Assersohn, Laura, Rigg, Anne, Sheri, Amna, Turner, Nick, Smith, Ian, Parton, Marina, Dowsett, Mitch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847032/
https://www.ncbi.nlm.nih.gov/pubmed/29128896
http://dx.doi.org/10.1007/s10549-017-4514-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847032/
https://www.ncbi.nlm.nih.gov/pubmed/29128896
http://dx.doi.org/10.1007/s10549-017-4514-z

Ejemplares similares